Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group

Journal of Clinical Oncology

Volumn 18, Issue 18, 2000, Pages 3262-3272

  Mattano L A , Jr ^a   Sather, Harland N ^a   Trigg, Michael E ^a   Nachman, James B ^a  

^a Michigan State University Kalamazoo Center for Medical Studies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAUCASIAN; CHILD; CHILDHOOD DISEASE; CORTICOSTEROID THERAPY; FEMALE; HUMAN; IMMOBILIZATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEGRO; PAIN; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK FACTOR; SEX RATIO;

EID: 0034666338     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.18.3262     Document Type: Article

References (94)

1. Ischemic necrosis of the femoral head
2. Steroid-induced osteoporosis
3. Osteonecrosis: Current perspectives on pathogenesis and treatment
4. Osteonecrosis of bone: Current concepts as to etiology and pathogenesis
5. Hematological consequences of long-term corticosteroid treatment
6. The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis: Clinical and experimental results
7. Avascular necrosis of the femoral and humeral heads after high-dosage corticosteroid therapy
8. The femoral head in osteonecrosis: A quantitative study of osteocyte population
9. The importance of increased intraosseous pressure in the development of osteonecrosis of the femoral head: Implications for treatment
10. Fat embolism and osteonecrosis
11. Steroid-induced accumulation of lipid in the osteocytes of the rabbit femoral head
12. Nontraumatic necrosis of bone (osteonecrosis)
13. Early diagnosis and treatment of steroid induced avascular necrosis of bone
14. Intramedullary haemorrhage as a possible cause of avascular necrosis of the femoral head: The histology of 16 femoral heads at the silent stage
15. Current concepts on the pathogenesis of osteonecrosis of the femoral head
16. Avascular necrosis and the blood supply of the femoral head
17. Early avascular necrosis of the femoral head: Report of a case and review of the literature
18. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits
19. Studies of nontraumatic osteonecrosis: The role of core decompression in the treatment of nontraumatic osteonecrosis of the femoral head
20. Experience with steroid-induced avascular necrosis of the shoulder and etiologic considerations regarding osteonecrosis of the hip
21. Idiopathic bone necrosis of the femoral head: Early diagnosis and treatment
22. Osteonecrosis, transient osteoporosis, and transient bone marrow edema: Current concepts
23. Natural history of nontraumatic avascular necrosis of the femoral head
24. Idiopathic necrosis of the femoral head: Pathogenesis and treatment
25. Avascular necrosis of the femoral head: Natural history and magnetic resonance imaging
26. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus
27. Total hip replacement in patients younger than thirty years old: A five-year follow-up study
28. Total hip arthroplasty after renal transplantation: Long-term follow-up study and assessment of metabolic bone status
29. Results of conservative management of osteonecrosis of the femoral head: A retrospective review
30. The use of glucocorticoids in acute lymphoblastic leukemia of childhood: Molecular, cellular, and clinical considerations
31. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: A report from the BFM Study Group
32. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features: Report of Children's Cancer Study Group Study CCG-193P
33. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Children's Cancer Group Study CCG-106
34. Ergebnisse der studie BFM 76/79 zur behandlung der akuten lymphoblastischen leukaemie bei kindern und jugendlichen
35. Therapie studie BFM 79/81 zu behandlung der akuten lymphoblastischen leukamie bei kindern und jugendlichen. Intensivierte reinduktions-therapie fur patienten gruppen mit unterschiedlichen rezidivrisko
36. Acute lymphoblastic leukemia in childhood: The COALL Therapy Studies
37. First results of the COALL-85 cooperative study for high-risk patients with acute lymphatic leukemia
38. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
39. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia
40. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Muenster and Dana-Farber Cancer Institute protocols
41. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: A report of three consecutive studies of the BFM Group
42. Acute lymphoblastic leukemia: Treatment results in three BFM studies (1970-1981)
43. Results and significance of six randomized trials in four consecutive ALL-BFM studies
44. Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood
45. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial
46. Glucocorticoid therapy
47. Problem der aseptischen Knochennekrosen bei Leukamiepatienten im Kindes-und Jugendalter
48. Incidence of aseptic osteonecrosis following the therapy of childhood leukemia
49. Aseptic osteonecrosis in the treatment of childhood acute leukemias
50. Avascular necrosis of bone following combination chemotherapy for acute lymphocytic leukemia
51. Avascular femoral head necrosis in pediatric cancer patients
52. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
53. Osteonecrosis in pediatric patients with acute lymphoblastic leukemia
54. Osteonecrosis in children treated for acute lymphoblastic leukemia: A magnetic resonance imaging study after treatment
55. Osteonecrosis during the treatment of childhood acute lymphoblastic leukemia: A prospective MRI study
56. Dexamethasone is much more potent than prednisolone in the assumed equivalent doses in childhood leukemia
57. Bone marrow magnetic resonance studies in childhood leukemia: Evaluation of osteonecrosis
58. Aseptic osteonecrosis in children treated for acute lymphoblastic leukemia and aplastic anemia
59. The West-Berlin therapy study of acute lymphoblastic leukemia in childhood: Report after 6 years
60. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976
61. Treatment of acute lymphoblastic leukemia: 30 Years' experience at St. Jude Children's Research Hospital
62. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01
63. Aseptische Knochennekrosen als Spatkomplikation nach erfolgreicher Behandlung von Leukamien und schwerer aplastischer Anamie
64. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen: A new intensive therapy protocol - A report from the Childrens Cancer Study Group
65. Osteonecrosis following chemotherapy for leukemia
66. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: Randomized controlled trial from the Children's Cancer Group
67. Lymphomatous presentation of childhood acute lymphoblastic leukemia: A subgroup at high risk of early treatment failure
68. Nonparametric estimation from incomplete observations
69. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples
70. Regression models and life tables
71. Steroid treatment and aseptic necrosis of the femoral head in renal transplant recipients
72. Orthopedic complications of renal transplantation in children
73. Author's response
74. Contrasting epidemiology of childhood osteosarcoma, Ewing's tumor, and rhabdomyosarcoma
75. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis
76. Vitamin D receptor gene polymorphism in men and its effect on bone density and calcium absorption
77. Vitamin D-receptor genotypes and bone density
78. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent
79. The glucocorticoid insensitivity syndrome
80. Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems
81. Prevention of hormone-induced hypercalcemia by use of methotrexate
82. Metabolic studies of the effects of methotrexate
83. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission
84. Characteristics of acute lymphoblastic leukemia in children with osteopenia and vertebral compression fractures
85. The spectrum of metabolic bone disease in lymphoblastic leukemia
86. Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children
87. Avascular bone necrosis in the renal transplant patient: A discriminant analysis of 144 cases
88. Bone-resorbing activity in supernatants from lymphoid cell lines
89. Effect of osteoclast activating factor from human leukocytes on bone metabolism
90. Autonomous production of parathyroid hormone by lymphoblastic leukemia cells in culture
91. Avascular necrosis of bone caused by combination chemotherapy without corticosteroids
92. Osteonecrosis of bone associated with combination chemotherapy without corticosteroids
93. Osteonecrosis after chemotherapy